Want to see LMAT full AI Analyst Report?
LMAT Stock Chart & Stats
$114.36
$0.87(0.94%)
At close: 4:00 PM EST
$114.36
$0.87(0.94%)
Day’s Range― - ―
52-Week Range$79.01 - $118.01
Previous CloseN/A
Volume40.91K
Average Volume (3M)344.75K
Market Cap
$2.35B
Enterprise Value$2.27B
Total Cash (Recent Filing)$367.23M
Total Debt (Recent Filing)$189.81M
Price to Earnings (P/E)37.2
Beta0.63
Next Earnings
Jul 23, 2026EPS Estimate
0.81Next Dividend Ex-DateN/A
Dividend Yield0.95%
Share Statistics
EPS (TTM)2.76
Shares Outstanding22,850,739
10 Day Avg. Volume318,310
30 Day Avg. Volume344,752
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)4.67
Price to Sales (P/S)7.36
P/FCF Ratio24.65
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue8.86
Enterprise Value/Gross Profit12.24
Enterprise Value/Ebitda23.57
Forecast
1Y Price Target
$123.00Price Target Upside7.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)3
Revenue Forecast (FY)$279.97M
Bulls Say, Bears Say
Bulls Say
High Profitability And Strong Free Cash FlowSustained ~72% gross margin and ~24% net margin with ~$79M TTM free cash flow indicate durable unit economics and high cash conversion. This supports reinvestment, dividends, and M&A funding without relying solely on new equity, improving long-term financial resilience.
Diversified Product Categories And Geographic ReachRecord regional results and across-category strength show demand diversification across geographies and products. Broad-based adoption reduces single-market risk, enlarges addressable market, and supports multi-year revenue growth as the company expands direct presence and international launches.
Operational Efficiency Driving Scalable MarginsAutomation and lean initiatives reduced labor while output rose, enabling persistent margin expansion as volumes scale. Structural manufacturing gains increase operating leverage, making incremental revenue more profitable and supporting durable operating-margin improvement over multiple quarters.
Bears Say
Material Increase In Leverage Since 2024A pronounced rise in leverage reduces financial flexibility, increases interest exposure, and narrows the margin for error on execution. If growth or cash flow weaken, higher debt amplifies downside risk and constrains strategic options like bolt-on M&A or incremental buybacks.
Regulatory And Rollout Execution Risk For Key ProductsLengthy regulatory timelines and staggered approvals delay large TAM expansions for Artegraft and slow RFA adoption in Europe. These structural execution risks can push out revenue milestones, compress multi-year upside, and increase required commercial investment before benefits materialize.
Variable Revenue Cadence And Distribution LumpinessAn inconsistent top-line cadence and lumpy distribution channels undermine predictability of recurring consumable demand. That variability complicates capacity planning, margins forecasting, and capital allocation, making sustained organic growth dependent on smoothing distribution and unit recovery.
Lemaitre Vascular News
LMAT FAQ
What was Lemaitre Vascular’s price range in the past 12 months?
Lemaitre Vascular lowest stock price was $79.00 and its highest was $118.01 in the past 12 months.
What is Lemaitre Vascular’s market cap?
Lemaitre Vascular’s market cap is $2.35B.
When is Lemaitre Vascular’s upcoming earnings report date?
Lemaitre Vascular’s upcoming earnings report date is Jul 23, 2026 which is in 10 days.
How were Lemaitre Vascular’s earnings last quarter?
Lemaitre Vascular released its earnings results on May 05, 2026. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.661 by $0.019.
Is Lemaitre Vascular overvalued?
According to Wall Street analysts Lemaitre Vascular’s price is currently Undervalued.
Does Lemaitre Vascular pay dividends?
Lemaitre Vascular pays a Quarterly dividend of $0.25 which represents an annual dividend yield of 0.95%. See more information on Lemaitre Vascular dividends here
What is Lemaitre Vascular’s EPS estimate?
Lemaitre Vascular’s EPS estimate is 0.81.
How many shares outstanding does Lemaitre Vascular have?
Lemaitre Vascular has 22,850,739 shares outstanding.
What happened to Lemaitre Vascular’s price movement after its last earnings report?
Lemaitre Vascular reported an EPS of $0.68 in its last earnings report, beating expectations of $0.661. Following the earnings report the stock price went down -1.589%.
Which hedge fund is a major shareholder of Lemaitre Vascular?
Currently, no hedge funds are holding shares in LMAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lemaitre Vascular Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$123.00 (7.56% Upside)
$123.00 (7.56% Upside)
Blogger Sentiment
Bullish
LMAT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 171.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.91%
12-Months-Change
Fundamentals
Return on Equity
16.19%
Trailing 12-Months
Asset Growth
13.22%
Trailing 12-Months
Company Description
Lemaitre Vascular
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
LMAT Stock 12 Month Forecast
Average Price Target
$123.00
▲(7.56% Upside)
Technical Analysis
Ownership Overview
6.90% Insiders
23.57% Mutual Funds
5.43% Other Institutional Investors
37.72% Public Companies and
Individual Investors








